After two setbacks earlier this year, Takeda finally reported good news on Ninlaro, its follow-up to now-off-patent blockbuster Velcade. In a phase 3 trial of the drug as a first-line maintenance treatment in multiple myeloma, patients experienced significant survival benefits.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,